• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测成人眼肌型重症肌无力广义转化的动态列线图。

Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.

机构信息

Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.

出版信息

Neurol Sci. 2023 Apr;44(4):1383-1391. doi: 10.1007/s10072-022-06519-5. Epub 2022 Dec 5.

DOI:10.1007/s10072-022-06519-5
PMID:36469201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10023757/
Abstract

PURPOSE

To explore the factors and risk mapping model of progression from ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) in adult-onset patients.

METHODS

A retrospective, observational cohort study was performed for 435 OMG patients with onset age older than 14 years old. Multivariate Cox regression was used to identify the independent factors affecting generalized conversions that then were incorporated into the construction of the nomogram.

RESULTS

Two hundred thirty-seven patients (54.5%) had transformed into GMG after a median of 1.1 years (range 0.1--9.1 years). The 6-, 12-, and 24-month generalized conversion rates were 31.7%, 49.8%, and 65.4%, respectively. Multivariable analysis showed that the early-onset age, male sex, concomitant autoimmune diseases (AID), positive results of anti-acetylcholine receptor antibodies, repetitive nerve stimulation abnormalities, the presence of thymoma, and prednisone treatment were significantly associated with the generalized conversions (hazard ratio [HR] = 0.598, 0.686, 1.554, 1.541, 2.020, 2.510, and 0.556, respectively). A nomogram was established to predict the possibility of generalization-free survival (GFS) in adult-onset OMG patients, and the model demonstrated good predictive performance with a C-index of 0.736 (95% confidence interval 0.703 ~ 0.769). Moreover, subgroup analyses were performed based on the presence or absence of prednisone therapy, and the results indicated that prednisone therapy has better prevention of generalized conversions in male, non-thymoma patients, and patients without other AID.

CONCLUSION

A new predictive nomograph and web-based survival calculator we developed show favorable applicability and accuracy in predicting long-term GFS in adult-onset OMG patients.

摘要

目的

探讨成人起病的眼肌型重症肌无力(OMG)向全身型重症肌无力(GMG)进展的相关因素及风险预测模型。

方法

回顾性观察队列研究纳入 435 例发病年龄>14 岁的 OMG 患者。采用多因素 Cox 回归分析影响 GMG 转化的独立因素,然后将这些因素纳入列线图的构建。

结果

237 例(54.5%)患者在中位 1.1 年(0.19.1 年)后转化为 GMG。6、12 和 24 个月的广义转化率分别为 31.7%、49.8%和 65.4%。多变量分析显示,早发年龄、男性、伴自身免疫性疾病(AID)、抗乙酰胆碱受体抗体阳性、重复神经电刺激异常、存在胸腺瘤和泼尼松治疗与 GMG 转化显著相关(风险比[HR]分别为 0.598、0.686、1.554、1.541、2.020、2.510 和 0.556)。建立了一个预测成人起病 OMG 患者无广义生存(GFS)可能性的列线图,模型具有良好的预测性能,C 指数为 0.736(95%置信区间 0.7030.769)。此外,根据是否使用泼尼松治疗进行了亚组分析,结果表明在男性、无胸腺瘤和无其他 AID 的患者中,泼尼松治疗对 GMG 转化的预防效果更好。

结论

我们开发的新预测列线图和基于网络的生存计算器在预测成人起病 OMG 患者的长期 GFS 方面具有良好的适用性和准确性。

相似文献

1
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.用于预测成人眼肌型重症肌无力广义转化的动态列线图。
Neurol Sci. 2023 Apr;44(4):1383-1391. doi: 10.1007/s10072-022-06519-5. Epub 2022 Dec 5.
2
Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.中国西北地区免疫抑制治疗下眼肌型重症肌无力的泛化预测。
BMC Neurol. 2020 Jun 11;20(1):238. doi: 10.1186/s12883-020-01805-1.
3
Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.成人眼肌型重症肌无力转化:中国单中心回顾性分析。
Eur Neurol. 2020;83(2):182-188. doi: 10.1159/000507853. Epub 2020 Jun 11.
4
Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.眼肌型重症肌无力胸腺切除术-预后和风险因素分析。
Orphanet J Rare Dis. 2022 Aug 9;17(1):309. doi: 10.1186/s13023-022-02454-y.
5
Response to treatment in pediatric ocular myasthenia gravis.小儿眼肌型重症肌无力的治疗反应。
Muscle Nerve. 2020 Feb;61(2):226-230. doi: 10.1002/mus.26745. Epub 2019 Nov 7.
6
Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.眼肌型重症肌无力的病情泛化风险:来自神经眼科诊所的经验
Acta Neurol Belg. 2022 Apr;122(2):337-344. doi: 10.1007/s13760-020-01582-1. Epub 2021 Feb 5.
7
Low conversion rate of ocular to generalized myasthenia gravis in Singapore.新加坡眼肌型重症肌无力向全身型转化的转化率低。
Muscle Nerve. 2018 May;57(5):756-760. doi: 10.1002/mus.25983. Epub 2017 Nov 2.
8
Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.影响乙酰胆碱受体抗体阳性的眼肌型重症肌无力患者泛化的因素。
Am J Ophthalmol. 2020 Jan;209:10-17. doi: 10.1016/j.ajo.2019.09.019. Epub 2019 Sep 25.
9
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.眼肌型重症肌无力患者2年后全身性疾病的发展情况。
Arch Neurol. 2003 Feb;60(2):243-8. doi: 10.1001/archneur.60.2.243.
10
Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.中国大样本儿童期起病型重症肌无力的临床特征、治疗和预后因素。
Pediatr Neurol. 2023 Sep;146:31-39. doi: 10.1016/j.pediatrneurol.2023.06.008. Epub 2023 Jun 16.

引用本文的文献

1
A Pilot Study on Predicting Ocular Hypertension in Chinese Patients Undergoing Femtosecond Laser-Assisted Penetrating Keratoplasty.一项关于预测接受飞秒激光辅助穿透性角膜移植术的中国患者高眼压的初步研究。
Int J Med Sci. 2025 Feb 24;22(6):1393-1403. doi: 10.7150/ijms.106586. eCollection 2025.
2
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases.病例报告:艾加莫德是治疗眼肌型重症肌无力的一种新的治疗选择:2例报告
Front Immunol. 2025 Jan 13;15:1497398. doi: 10.3389/fimmu.2024.1497398. eCollection 2024.
3
A Nomogram Model for Predicting the Polyphenol Content of Pu-Erh Tea.

本文引用的文献

1
[Simulation study on missing data imputation methods for longitudinal data in cohort studies].队列研究中纵向数据缺失值插补方法的模拟研究
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1889-1894. doi: 10.3760/cma.j.cn112338-20201130-01363.
2
Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.胸腺瘤切除术和眼肌型重症肌无力患者泛化的风险:一项多中心回顾性队列研究。
Neurotherapeutics. 2021 Oct;18(4):2449-2457. doi: 10.1007/s13311-021-01129-z. Epub 2021 Oct 8.
3
Ocular myasthenia gravis - How effective is low dose prednisone long term?
一种预测普洱茶多酚含量的列线图模型。
Foods. 2023 May 25;12(11):2128. doi: 10.3390/foods12112128.
眼肌型重症肌无力——小剂量泼尼松长期疗效如何?
J Neurol Sci. 2021 Jan 15;420:117274. doi: 10.1016/j.jns.2020.117274. Epub 2020 Dec 17.
4
Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.中国西北地区免疫抑制治疗下眼肌型重症肌无力的泛化预测。
BMC Neurol. 2020 Jun 11;20(1):238. doi: 10.1186/s12883-020-01805-1.
5
Update on Ocular Myasthenia Gravis.眼肌型重症肌无力的最新进展。
Semin Neurol. 2019 Dec;39(6):749-760. doi: 10.1055/s-0039-1700527. Epub 2019 Dec 17.
6
Assessment of pre and post-thymectomy myasthenia gravis.胸腺切除术前和术后重症肌无力的评估
Neurol Res. 2019 Mar;41(3):275-281. doi: 10.1080/01616412.2018.1557433. Epub 2018 Dec 21.
7
Generalization after ocular onset in myasthenia gravis: a case series in Germany.眼肌型重症肌无力发病后的泛化:德国的一项病例系列研究。
J Neurol. 2018 Dec;265(12):2773-2782. doi: 10.1007/s00415-018-9056-8. Epub 2018 Sep 17.
8
Treatment of Ocular Myasthenia Gravis.眼肌型重症肌无力的治疗。
Asia Pac J Ophthalmol (Phila). 2018 Jul-Aug;7(4):257-259. doi: 10.22608/APO.2018301. Epub 2018 Jul 25.
9
Antibody profile may predict outcome in ocular myasthenia gravis.抗体谱可能预测眼肌型重症肌无力的预后。
Acta Neurol Belg. 2018 Sep;118(3):435-443. doi: 10.1007/s13760-018-0943-7. Epub 2018 Jun 1.
10
Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology.全身型重症肌无力:分类、临床表现、自然史及流行病学
Neurol Clin. 2018 May;36(2):253-260. doi: 10.1016/j.ncl.2018.01.002.